Life Science Leader Chief Editor Blog Header image Life Science Leader Chief Editor Blog Header image

Despite Delays, JPM 2017 Still Pays Off For Me
Despite Delays, JPM 2017 Still Pays Off For Me For the second year in a row my travel plans to the biopharmaceutical industry’s yearly kickoff event — the 35th Annual J. P. Morgan Healthcare Conference in San Francisco —was disrupted by weather. And though I once again arrived a day late, there was still plenty to keep me busy during JPM. For example, I still had the opportunity to sit in breakout Q&A sessions involving Alkermes, BMS, Chimerix, GSK, Mylan NV, and Shire. ...  Continue Reading...
Why “Partnering For Cures” Is A Highly Differentiated Experience
Why “Partnering For Cures” Is A Highly Differentiated Experience Two weeks ago I went to the Partnering For Cures (Nov. 13 – 15) conference at the Grand Hyatt in New York. After the experience, it is almost painful to admit that this was my first time attending. Developed by Faster Cures and the Milken Institute, the conference (now in existence for over eight years) brings together nearly 1,000 leaders from across the research ecosystem. The event’s goal is to forge partnerships dedicated to...  Continue Reading...
Trump Wins: What Can Pharma Hope For In The Next 4 Years?
Trump Wins: What Can Pharma Hope For In The Next 4 Years? On November 14, 2016, Carolyn Johnson posted “Trump just dropped a big hint to the pharmaceutical industry” in a wonkblog for The Washington Post. I shared the article on LinkedIn (receiving over 415 views) noting, “It is very early days, so let’s not get too excited or too concerned. But let’s be aware and strive to be part of the solution for helping patients.” This seemed like a natural fit to share...  Continue Reading...
6 Lessons Learned From Posting A Picture That Went Viral On LinkedIn
6 Lessons Learned From Posting A Picture That Went Viral On LinkedIn A little over a week ago, I posted a picture to my LinkedIn profile, which has since received over 60,000 views. And while there are mathematical calculations to officially determine when a post has gone viral, the fact that it has been viewed (and commented on) more widely than anything I have ever previously published is very humbling, especially considering the nature of the photo (i.e., a fallen U.S. service member) is far outside of what I...  Continue Reading...
How The Biopharmaceutical Industry Provides A Sparkle Of Hope
How The Biopharmaceutical Industry Provides A Sparkle Of Hope Author Steven Covey’s famous phrase, “To Live, To Love, To Learn, To Leave a Legacy” is what popped into my head while attending the Community of Hope’s Annual Dinner Auction as the invited guest of pharmaceutical industry icon, Fred Hassan. Twenty years ago Hassan founded this annual charity event that brings together two communities (i.e., social services and the biopharmaceutical industry) to do good in their own...  Continue Reading...
Will Cuba Be The World’s Next Leading Biotech Hub?
Will Cuba Be The World’s Next Leading Biotech Hub? Life Science Leader magazine was recently invited to attend The Economist’s War On Cancer healthcare forum in Boston, Sept. 28, 2016. Though all of the day’s sessions were intriguing, the one that got me up out of my chair to track down a speaker before his exit occurred at 4 p.m. Entitled, “Going Global – Examples Of Cancer Advances From Around The World,” the first person to speak was Kelvin Lee, M.D., immunology...  Continue Reading...
What I Found Enlightening About ISPE’s Annual Meeting
What I Found Enlightening About ISPE’s Annual Meeting Have you ever attended a meeting and gotten the sense of being enlightened during someone’s presentation? I recently had such an experience at the International Society for Pharmaceutical Engineering (ISPE) annual meeting and expo in Atlanta, GA. But it was neither where I expected it, nor whom I expected it from (e.g.,, keynote speakers). Don’t get me wrong, Joseph Jimenez, Dr. Stephan Grupp, M.D., Ph.D., Nicole Pierson, and Fleming ...  Continue Reading...
Beyond IPOs: Alternative Funding Options For Biotech Startups
Beyond IPOs: Alternative Funding Options For Biotech Startups “While it is great when Morgan Stanley, JP Morgan, and Goldman are fighting to take your company public, sometimes, given the investment environment, you have to play in a ‘less elegant’ part of the finance swimming pool (e.g., Form 10s and reverse mergers).” This statement by Aftab Kherani, M.D., a partner at Aisling Capital, was made in response to the question, “What are some of the more innovative ways companies ...  Continue Reading...
Can A Better Patient Experience Lead To A Better Patient Outcome?
Can A Better Patient Experience Lead To A Better Patient Outcome? My colleague, Ed Miseta, chief editor of Clinical Leader, recently asked, “Can Better Patient Experiences Lead To Better Medicines?” via an article he developed from an interview with Thomas Goetz, cofounder of Iodine, a digital health company. According to Miseta, Goetz is attempting to turn patient experiences into better medicines and is combining data and design to help patients locate the best treatments based on preferences,...  Continue Reading...
Rare Situation Results In Free Insights From GSK’s Global Vaccine President
Rare Situation Results In Free Insights From GSK’s Global Vaccine President When conducting interviews my natural curiosity can result in a surplus of interesting content that often doesn’t fit with the overall theme of the final published article. When situations like these happen, I often proactively create articles for an online section called — From The Cutting Room Floor. One of my favorite examples of a cutting room floor article being able to provide valuable insight came from an interview with George ...  Continue Reading...